Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
CYP3A7 1551 CORTISONE ACETATE CHEMBL1650 PharmGKB
CYP3A7 1551 COBICISTAT CHEMBL2095208 inhibitor ChemblInteractions
CYP3A7 1551 TESMILIFENE CHEMBL26424 TdgClinicalTrial
CYP3A7 1551 MELATONIN CHEMBL45 NCI 11882353
CYP3A7 1551 QUININE CHEMBL170 NCI 9863152
CYP3A7 1551 MICONAZOLE CHEMBL91 NCI 3263862
CYP3A7 1551 WARFARIN CHEMBL1464 NCI 3977899

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
CYP3A7 rs45446698 G atorvastatin metabolism/PK yes This variant was associated with increased metabolic ratios of 2-OH ATV/ATV (P = 6.18 × 10−7) (increased hydroxylation of ATV) at genome-wide significance. Allele G is associated with increased metabolism of atorvastatin as compared to allele T. 32128760 1451163221
CYP3A7 rs10211 TT tacrolimus metabolism/PK yes The CYP3A7 gene is on the negative strand of the chromosome. Alleles in this gene are complimented to the positive chromosomal strand in PharmGKB annotations. Tacrolimus concentration among CYP3A7 rs10211 C non-carriers is almost twofold as compared to the C carriers. (101.8 vs 59.6, P=0.0004). Genotype TT are associated with increased concentrations of tacrolimus in children with null as compared to genotypes CC + CT. 31401678 1450928448
CYP3A7 CYP3A7*1A, CYP3A7*1C *1C cortisone acetate dosage yes CYP3A7 *1C is associated with decreased dose of cortisone acetate in children with Adrenal Hyperplasia, Congenital as compared to CYP3A7 *1A. 21915484 827806085
CYP3A7 rs2257401 CG + GG tacrolimus metabolism/PK yes The CYP3A7 gene is on the negative strand of the chromosome. Alleles in this gene are complimented to the positive chromosomal strand in PharmGKB annotations. Genotypes CG + GG are associated with decreased concentrations of tacrolimus in children with null as compared to genotype CC. 31401678 1450928424
CYP3A7 CYP3A7*1A, CYP3A7*1C *1C risperidone metabolism/PK no No association was found between this * allele and risperidone, 9-hydroxy-risperidone or active moiety plasma levels, risperidone/9-hydroxy-risperidone ratio, or dose requirements (data not shown). CYP3A7 *1C is not associated with clearance of risperidone in people with Psychotic Disorders as compared to CYP3A7 *1A. 23609392 1183699464
CYP3A7 CYP3A7*1A, CYP3A7*1C *1C/*1C donepezil metabolism/PK no Diplotypes *1/*1, *1/*1C, *1C/*1C, did not influence donepezil clearance in a covariate model. CYP3A7 *1C/*1C is not associated with clearance of donepezil in people with Alzheimer Disease as compared to CYP3A7 *1A/*1A. 24433464 1184511064
CYP3A7 rs2257401 CC cyclosporine metabolism/PK yes for C2/D at 6 and 24 months. Patients were also receiving mycophenolate mofetil and prednisone. CAUTION: this is C/G SNP on minus strand, complemented here compared to paper to show on plus chromosomal strand. Genotype CC is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes CG + GG. 28952408 1448997408
CYP3A7 rs10211 TT cyclosporine metabolism/PK yes for C0/D at 0, 6 months and 24 months. Patients were also receiving mycophenolate mofetil and prednisone. Genotype TT is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes CC + CT. 28952408 1448997399
CYP3A7 rs2257401 C tacrolimus metabolism/PK yes This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients, this passed validation in the EA cohort. Direction of effect was not stated. Allele C is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G. 29318894 1449163553
CYP3A7 CYP3A7*1A, CYP3A7*1C *1A/*1A tacrolimus metabolism/PK yes Dose-corrected tacrolimus exposure (AUC0-12/doseBW). CYP3A7 *1A/*1A is associated with decreased concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A7 *1A/*1C + *1C/*1C. 27966227 1449171382
CYP3A7 CYP3A7*1A, CYP3A7*1C *1C etonogestrel "efficacy","metabolism/PK" no "Carriers of CYP3A7*1C had, on average, 23% lower etonogestrel concentrations than participants with the wild-type genotype" in contraceptive implant users which may theoretically put them at risk for contraceptive failure. Corrected P-value cutoff of 5.0E-4 was not met. CYP3A7 *1C is associated with decreased steady-state concentration of etonogestrel in women as compared to CYP3A7 *1A/*1A. 30870275 1450375830